Stay updated on APL-2 vs Sham in GA: Efficacy & Safety Clinical Trial
Sign up to get notified when there's something new on the APL-2 vs Sham in GA: Efficacy & Safety Clinical Trial page.

Latest updates to the APL-2 vs Sham in GA: Efficacy & Safety Clinical Trial page
- CheckyesterdayChange DetectedThe site revision shown in the footer changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check8 days agoChange DetectedAn NIH-wide banner was added announcing updates and FAQs about the agency’s terminology transition from “Artificial Intelligence” to “Super Intelligence.” The page content otherwise remains a 403 error.SummaryDifference1%

- Check15 days agoChange DetectedThe footer's site revision identifier changes from v3.7.1 to v3.7.2; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedThe ClinicalTrials.gov page continues to display a 403 Forbidden error, with the footer showing revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check43 days agoChange DetectedThis page now shows a 403 Forbidden error instead of the study details, indicating the study record at this URL is inaccessible. The change prevents viewing core study information on this page.SummaryDifference17%

- Check57 days agoChange DetectedA new publication citation has been added under Publications From PubMed for Syfovore approval for geographic atrophy (JAMA Ophthalmol. 2024). This provides updated literature context related to GA therapies.SummaryDifference0.0%

Stay in the know with updates to APL-2 vs Sham in GA: Efficacy & Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APL-2 vs Sham in GA: Efficacy & Safety Clinical Trial page.